Complement and granulocyte activation in two different types of heparinized extracorporeal circuits. 1995

E Ovrum, and T E Mollnes, and E Fosse, and E A Holen, and G Tangen, and M Abdelnoor, and M A Ringdal, and R Oystese, and P Venge
Department of Cardiac Surgery and Anesthesiology, Oslo Heart Center, Norway.

Complement and granulocyte activation were studied in cardiopulmonary bypass circuits completely coated with either end-attached covalent-bonded heparin, the Carmeda BioActive Surface, or with the Duraflo II bonded heparin, in combination with reduced systemic heparinization (activated clotting time > 250 seconds). The control groups were perfused with uncoated circuits and full heparin dose (activated clotting time > 480 seconds). Altogether 67 patients undergoing elective first-time myocardial revascularization were investigated, having extracorporeal perfusion with a Duraflo II coated circuit (n = 17), an identical but uncoated circuit (n = 17), a Carmeda coated circuit (n = 17), or an equivalent uncoated circuit (n = 16). During cardiopulmonary bypass, the C3 activation products C3b, iC3b, and C3c (C3bc) and the terminal SC5b-9 complemented complex increased markedly in all four groups compared with baseline, but significantly less in the two coated groups than in their control groups. Additionally, a significantly lower concentration of C3bc was observed in the Carmeda coated group, with maximal increase of median 28 AU/ml compared with 50 AU/ml in the Duraflo II coated group (p = 0.003). Similarly, in the Carmeda coated group, the maximal increase of terminal complement complex was considerably lower (0.8 AU/ml) than the levels recognized in the Duraflo II coated group (2.4 AU/ml) (p < 0.001). The release of the granulocyte activation myeloperoxidase and lactoferrin increased from the beginning of the operation, with peak levels at the end of bypass. A significant reduction of lactoferrin release was recognized when comparing the coated groups with the control groups. The difference between the two coated groups (Carmeda 228 micrograms/L; Duraflo II 332 micrograms/L; p = 0.05) was marginally significant. For myeloperoxidase, no significant differences were observed between the coated and uncoated groups. In conclusion, both types of heparin-coated circuits reduced complement activation and release of lactoferrin, but the Carmeda circuit proved to be more effective than the Duraflo II equipment.

UI MeSH Term Description Entries
D007781 Lactoferrin An iron-binding protein that was originally characterized as a milk protein. It is widely distributed in secretory fluids and is found in the neutrophilic granules of LEUKOCYTES. The N-terminal part of lactoferrin possesses a serine protease which functions to inactivate the TYPE III SECRETION SYSTEM used by bacteria to export virulence proteins for host cell invasion. Lactotransferrin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009195 Peroxidase A hemeprotein from leukocytes. Deficiency of this enzyme leads to a hereditary disorder coupled with disseminated moniliasis. It catalyzes the conversion of a donor and peroxide to an oxidized donor and water. EC 1.11.1.7. Myeloperoxidase,Hemi-Myeloperoxidase,Hemi Myeloperoxidase
D002315 Cardiopulmonary Bypass Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs. Heart-Lung Bypass,Bypass, Cardiopulmonary,Bypass, Heart-Lung,Bypasses, Cardiopulmonary,Bypasses, Heart-Lung,Cardiopulmonary Bypasses,Heart Lung Bypass,Heart-Lung Bypasses
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D005260 Female Females
D006098 Granulocytes Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS. Granulocyte
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin

Related Publications

E Ovrum, and T E Mollnes, and E Fosse, and E A Holen, and G Tangen, and M Abdelnoor, and M A Ringdal, and R Oystese, and P Venge
January 1987, Annals of the New York Academy of Sciences,
E Ovrum, and T E Mollnes, and E Fosse, and E A Holen, and G Tangen, and M Abdelnoor, and M A Ringdal, and R Oystese, and P Venge
November 1998, Perfusion,
E Ovrum, and T E Mollnes, and E Fosse, and E A Holen, and G Tangen, and M Abdelnoor, and M A Ringdal, and R Oystese, and P Venge
January 1993, Clinical materials,
E Ovrum, and T E Mollnes, and E Fosse, and E A Holen, and G Tangen, and M Abdelnoor, and M A Ringdal, and R Oystese, and P Venge
June 1986, Clinical nephrology,
E Ovrum, and T E Mollnes, and E Fosse, and E A Holen, and G Tangen, and M Abdelnoor, and M A Ringdal, and R Oystese, and P Venge
October 1998, Journal of cardiothoracic and vascular anesthesia,
E Ovrum, and T E Mollnes, and E Fosse, and E A Holen, and G Tangen, and M Abdelnoor, and M A Ringdal, and R Oystese, and P Venge
April 1996, The Annals of thoracic surgery,
E Ovrum, and T E Mollnes, and E Fosse, and E A Holen, and G Tangen, and M Abdelnoor, and M A Ringdal, and R Oystese, and P Venge
September 1993, The Journal of thoracic and cardiovascular surgery,
E Ovrum, and T E Mollnes, and E Fosse, and E A Holen, and G Tangen, and M Abdelnoor, and M A Ringdal, and R Oystese, and P Venge
June 1976, Scandinavian journal of immunology,
E Ovrum, and T E Mollnes, and E Fosse, and E A Holen, and G Tangen, and M Abdelnoor, and M A Ringdal, and R Oystese, and P Venge
April 2020, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society,
E Ovrum, and T E Mollnes, and E Fosse, and E A Holen, and G Tangen, and M Abdelnoor, and M A Ringdal, and R Oystese, and P Venge
December 2006, Perfusion,
Copied contents to your clipboard!